Identification of Potential Therapeutic Targets in the Liver of Pioglitazone-Treated Type 2 Diabetes Sprague-Dawley Rats via Expression Profile Chip and iTRAQ Assay

الملخص EN

The aim of the present study was to identify key antidiabetic nodes in the livers of pioglitazone-treated type 2 diabetes mellitus Sprague-Dawley rats by transcriptomic and proteomic analysis.

Rats were randomly divided into the control, the diabetes model, and the pioglitazone-treated groups.

After treatment with pioglitazone for 11 weeks, the effects on fasting blood glucose, body weight, and blood biochemistry parameters were evaluated.

Microarray and iTRAQ analysis were used to determine the differentially expressed genes/proteins in rat livers.

1.5-fold changes in gene expression and 1.2-fold changes in protein were set as the screening criteria.

After treatment with pioglitazone for 11 weeks, fasting blood glucose in pioglitazone-treated rats was significantly lower than that in the model group.

There was a tendency for pioglitazone to reduce TC, TG, TP, ALB, BUN, and HDL-c levels.

Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO) were applied to analyze differentially expressed genes/proteins.

Furthermore, Western blotting and RT-qPCR were used to validate the results of microarray and iTRAQ.

In conclusion, Cyp7a1, Cp, and RT1-EC2 are differentially expressed genes/proteins since they showed a similar trend in rats in the model group and the pioglitazone-treated group.